TDS0593

TDS0593 is a first-in-class proteolysis-targeting chimera (PROTAC) designed to degrade the Src homology 2 domain-containing phosphatase 2 (SHP2). Developed by Beijing Tide Pharmaceutical, TDS0593 addresses the limitations of traditional SHP2 inhibitors, which only target phosphatase-dependent activities, by inducing complete degradation of the SHP2 protein. This approach targets both phosphatase-dependent and -independent roles of SHP2, which is a key mediator in tumor signaling pathways and a suppressor of PD-1. Preclinical studies in myeloid leukemia models (e.g., MV411) and solid tumor PDX models have demonstrated potent antitumor efficacy and the ability to correct aberrant myeloid-biased differentiation of hematopoietic stem cells.